Company Update (NYSE:PFE): Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery

[Business Wire] – Pfizer Inc. announced today enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus multi-antigen vaccine in adults undergoing elective spinal fusion surgery. Read . . . → Read More: Company Update (NYSE:PFE): Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery Similar Articles: Stock Update (NYSE:PFE): Pfizer Declares 28-Cent Third-Quarter 2015 Dividend Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Company Update (NYSE:PFE): Pfizer, Lilly to resume late-stage study testing pain drug